Novartis opens the world's largest centre for respiratory research in Horsham, UK
At an inauguration ceremony in Horsham today, UK Minister of State for Social Care John Hutton opened the new
Novartis centre for respiratory research, the world's largest single-site centre devoted to research of this kind. The GBP 40 million (CHF 100 million) facility
in the South of England will bring together 180 international scientists to spearhead research into new treatments for diseases such as asthma and chronic
obstructive pulmonary disease (COPD).
"We believe that the Novartis Respiratory Research Centre offers great promise for the discovery and development of the next generation of treatments for
sufferers of respiratory disease," said Paul Herrling, worldwide Head of Research at Novartis Pharma. "It builds on the breakthrough science that has led to
innovative products such as Foradil®, the first and only fast-acting, long-lasting bronchodilator, and Xolair®, our novel anti-IgE currently in development for
allergic asthma and rhinitis."
Respiratory illnesses are growing at an alarming rate. Nearly 150 million people around the world are afflicted with asthma today. In less than twenty years this
number will double to roughly the current population of the United States.1 Other conditions such as COPD, which kills 2.5 million people annually, is the
fourth leading cause of death in the developed world.1,2
"The need for this type of vital research is illustrated by the recent AIRE study that shows, despite receiving treatment, 46% of asthma sufferers still have
day-time symptoms, when the goal should be elimination and reduction of these symptoms", said Professor Peter Barnes, Director of the Department of
Thoracic Medicine at the National Heart and Lung Institute, London, who spoke at the opening.
The Novartis Respiratory Research Centre has attracted leading experts in the field, and will be led by Professor John Westwick, formerly head of Pharmacy
and Pharmacology at Bath University, UK. Professor Westwick is best known for his research and extensive publications on the molecular mechanisms of
inflammation and pioneering studies into the functional significance of ion channels in inflammatory cells.
Orion Corporation has filed a patent infringement lawsuit in the United States to enforce its formulation patent, U.S. Patent No. 6,500,867, against Sun Pharmaceutical Industries Inc. and Sun Pharmaceutical Industries Limited, who seek to market generic versions of Stalevo® tablets (25/100/ ... more
Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million.
As part of the transaction, which was anno ... more
Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technolo ... more